Most Read Articles
3 days ago
New drug applications approved by US FDA as of 01 - 15 June 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date. 
Audrey Abella, 3 days ago
The taxane-based TPEx regimen demonstrated encouraging overall survival (OS) benefit for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) compared with the fluorouracil (5FU)-based EXTREME regimen, according to the results of the TPExtreme* trial presented at ASCO 2019.

Contemporary combined hormonal contraceptives protect against ovarian cancer

07 Oct 2018

Contemporary combined hormonal contraceptives, such as desogestrel, gestodene and drospirenone, reduce the risk of ovarian cancer in women of reproductive age, a recent study has shown.

Researchers enrolled 1,879,227 women aged 15–49 years and who had no cancer, venous thrombosis or infertility treatments. Poisson regression analysis was performed to determine the risk of ovarian cancer among those who used any contemporary combined hormonal contraceptives.

Over the study duration of 20 years (21.4 million person-years), researchers documented 1,249 incident ovarian cancers in the study population, with the median age at diagnosis being 44.4 years.

Stratified analysis showed that in never users of any hormone contraceptives, 771 incident ovarian cancers developed over 8,150,250 person-years of follow-up. In comparison, 478 cases over 13,344,531 person-years were reported among ever users.

Moreover, the age-adjusted incidence rate of ovarian cancer was higher in never users vs ever users of any hormonal contraception (7.5 vs 4.3 per 100,000 person-years), resulting in a significant risk difference (adjusted relative risk [RR], 0.66; 95 percent CI, 0.58–0.76).

The protective effect of hormonal contraceptives against ovarian cancer was stronger for women who took combined oral (adjusted RR, 0.53; 0.45–0.64) than progestogen-only (adjusted RR, 0.72; 0.55–0.95) products.

Notably, the effect was diminished with time since last contraceptive use. The risk of ovarian cancer was comparable between never users and ever users by 10 years since last reported use of any hormonal contraception (adjusted RR, 0.80; 0.59–1.08).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
New drug applications approved by US FDA as of 01 - 15 June 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date. 
Audrey Abella, 3 days ago
The taxane-based TPEx regimen demonstrated encouraging overall survival (OS) benefit for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) compared with the fluorouracil (5FU)-based EXTREME regimen, according to the results of the TPExtreme* trial presented at ASCO 2019.